Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Personalizing medicine for metastatic colorectal cancer: current developments.

World journal of gastroenterology - 14 Aug 2014

Marques Andrea Marin, Turner Alice, de Mello Ramon Andrade

Abstract excerpt

Metastatic colorectal cancer (mCRC) is still one of the tumor types with the highest incidence and mortality. In 2012, colorectal cancer was the second most prevalence cancer among males (9%) and the third among females (8%). In this disease, early diagnosis is important to improve treatment outcomes. However, at the time of diagnosis, about one quarter of patients already have metastases, and overall survival of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Agents
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Precision Medicine

Share to Predictive Value of Tests

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 25132758
DOI: 10.3748/wjg.v20.i30.10425
PMCID: PMC4130849

Genes

KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Personalizing medicine for metastatic colorectal cancer: current developments.PMID 25132758Read ↗

A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistanceSemantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015.Semantic proximity Read ↗

Metastatic colorectal cancer: current state and future directions.Semantic proximity Read ↗

Targeting BRAF V600E in metastatic colorectal cancer: where are we today?Semantic proximity Read ↗

Current and Emerging Treatment Paradigms in Colorectal Cancer: Integrating Hallmarks of CancerSemantic proximity Read ↗

A review on emerging targeted therapies for the management of metastatic colorectal cancers.Semantic proximity Read ↗

Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019.Semantic proximity Read ↗

[What are the new therapeutic strategies in metastatic colorectal cancer including biotherapies?].Semantic proximity Read ↗

Clinical research progress on BRAF V600E-mutant advanced colorectal cancer.Semantic proximity Read ↗

Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients.Semantic proximity Read ↗

New Developments in Treating RAS-Mutated Metastatic Colorectal Cancer.Semantic proximity Read ↗

Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.